WO2005060960A3 - Use of histamine to treat bone disease - Google Patents

Use of histamine to treat bone disease Download PDF

Info

Publication number
WO2005060960A3
WO2005060960A3 PCT/US2004/041092 US2004041092W WO2005060960A3 WO 2005060960 A3 WO2005060960 A3 WO 2005060960A3 US 2004041092 W US2004041092 W US 2004041092W WO 2005060960 A3 WO2005060960 A3 WO 2005060960A3
Authority
WO
WIPO (PCT)
Prior art keywords
histamine
bone disease
treat bone
bone tissue
cell damage
Prior art date
Application number
PCT/US2004/041092
Other languages
French (fr)
Other versions
WO2005060960A2 (en
Inventor
Kurt R Gehlsen
Original Assignee
Maxim Pharm Inc
Kurt R Gehlsen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxim Pharm Inc, Kurt R Gehlsen filed Critical Maxim Pharm Inc
Publication of WO2005060960A2 publication Critical patent/WO2005060960A2/en
Publication of WO2005060960A3 publication Critical patent/WO2005060960A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine

Abstract

Described herein are methods for treating and/or preventing bone tissue and cell damage caused by reactive oxygen species in mammals. More specifically, embodiments of the invention relate to the prevention and/or reduction of bone tissue and cell damage through the administration of histamine, histamine agonists, and related compounds.
PCT/US2004/041092 2003-12-11 2004-12-08 Use of histamine to treat bone disease WO2005060960A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52920503P 2003-12-11 2003-12-11
US60/529,205 2003-12-11

Publications (2)

Publication Number Publication Date
WO2005060960A2 WO2005060960A2 (en) 2005-07-07
WO2005060960A3 true WO2005060960A3 (en) 2005-11-17

Family

ID=34710113

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/041092 WO2005060960A2 (en) 2003-12-11 2004-12-08 Use of histamine to treat bone disease

Country Status (2)

Country Link
US (1) US20050171192A1 (en)
WO (1) WO2005060960A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110111007A1 (en) * 2005-04-29 2011-05-12 Mcginnis James F Inhibition of retinal cell degeneration or neovascularization by cerium oxide nanoparticles
US7959949B2 (en) 2006-04-27 2011-06-14 University Of Central Florida Research Foundation, Inc. Functionalized nanoceria composition for ophthalmic treatment
US9119391B1 (en) 2007-07-16 2015-09-01 University Of Central Florida Research Foundation, Inc. Polymer coated ceria nanoparticles for selective cytoprotection
US8916199B1 (en) 2008-04-25 2014-12-23 University of Central Florida Research Foundation, Ind. Inhibition of angiogenesis associated with ovarian cancer by nanoparticles of cerium oxide
EP2288258A4 (en) * 2008-04-25 2012-10-31 Univ Oklahoma Inhibition of neovascularization by cerium oxide nanoparticles
US9127202B1 (en) 2008-07-18 2015-09-08 University Of Central Florida Research Foundation, Inc. Biocompatible nano rare earth oxide upconverters for imaging and therapeutics
US8883519B1 (en) 2009-03-17 2014-11-11 University Of Central Florida Research Foundation, Inc. Oxidase activity of polymeric coated cerium oxide nanoparticles
US9585840B1 (en) 2009-07-10 2017-03-07 University Of Central Florida Research Foundation, Inc. Redox active cerium oxide nanoparticles and associated methods
US8795731B1 (en) 2009-10-12 2014-08-05 University Of Central Florida Research Foundation, Inc. Cerium oxide nanoparticle-based device for the detection of reactive oxygen species and monitoring of chronic inflammation
EP2544542A4 (en) * 2010-03-10 2013-07-24 Galleon Pharmaceuticals Inc Analgesic compounds, compositions, and uses thereof
US8877207B2 (en) 2010-09-17 2014-11-04 University Of Central Florida Research Foundation, Inc. Nanoparticles of cerium oxide targeted to an amyloid-beta antigen of Alzheimer's disease and associated methods
US8951539B1 (en) 2011-06-07 2015-02-10 University Of Central Florida Research Foundation, Inc. Methods of promoting angiogenesis using cerium oxide nanoparticles
US9161950B2 (en) 2011-09-21 2015-10-20 University Of Central Florida Foundation, Inc. Neuronal protection by cerium oxide nanoparticles
US9463437B2 (en) 2013-02-14 2016-10-11 University Of Central Florida Research Foundation, Inc. Methods for scavenging nitric oxide using cerium oxide nanoparticles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407133B2 (en) * 1999-01-08 2002-06-18 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4573996A (en) * 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4597961A (en) * 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US5122127A (en) * 1985-05-01 1992-06-16 University Of Utah Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US5312325A (en) * 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US4839174A (en) * 1987-10-05 1989-06-13 Pharmetrix Corporation Novel transdermal nicotine patch
US4943435A (en) * 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US4908213A (en) * 1989-02-21 1990-03-13 Schering Corporation Transdermal delivery of nicotine
US5679337A (en) * 1991-06-14 1997-10-21 Professional Pharmaceutical, Inc. Method and composition for topical treatment of Aphthous stomatitis histamine using phosphate as active ingredient
CA2103163C (en) * 1991-08-26 1998-10-20 Mou-Ying Fu Lu Compositions and methods for the sublingual or buccal administration of therapeutic agents
CA2075517C (en) * 1992-04-01 1997-03-11 John Wick Transdermal patch incorporating a polymer film incorporated with an active agent
SE513429C2 (en) * 1992-06-03 2000-09-11 Syntello Inc Preparations for activating natural killer cells, which contain interferon alfa and biogenic amines
US5474527A (en) * 1993-03-29 1995-12-12 Bettinger; David S. Positive displacement transdermal system
US5549906A (en) * 1993-07-26 1996-08-27 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
EP0759939B1 (en) * 1994-05-18 2005-07-20 Nektar Therapeutics Methods and compositions for the dry powder formulation of interferons
FI95441C (en) * 1994-05-31 1996-02-12 Leiras Oy Inhaler drug chamber
US5804203A (en) * 1994-12-21 1998-09-08 Cosmederm Technologies Topical product formulations containing strontium for reducing skin irritation
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US6155266A (en) * 1995-05-08 2000-12-05 Maxim Pharmaceuticals, Inc. Method for treatment of cancer and infectious disease
CA2392466C (en) * 1995-12-07 2004-05-04 Jago Research Ag Inhaler for multiple dosed administration of a pharmacological dry powder
US5871010A (en) * 1996-06-10 1999-02-16 Sarnoff Corporation Inhaler apparatus with modified surfaces for enhanced release of dry powders
GB9626233D0 (en) * 1996-12-18 1997-02-05 Chawla Brinda P S Medicament packaging and deliveery device
DE19710631B4 (en) * 1997-03-14 2006-02-09 Zf Sachs Ag Quick release for mounting a pressure medium cylinder to a housing

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407133B2 (en) * 1999-01-08 2002-06-18 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage

Also Published As

Publication number Publication date
US20050171192A1 (en) 2005-08-04
WO2005060960A2 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
WO2002044187A3 (en) Cyclic salen-metal compounds as scavengers for oxygen radicals and useful as antioxidants in the treatment and prevention of diseases
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
WO2004093831A3 (en) Cytokine-expressing cellular vaccine combinations
WO2001087328A3 (en) Interleukin-1 inhibitors in the treatment of diseases
WO2005060960A3 (en) Use of histamine to treat bone disease
WO2005011734A3 (en) Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer
WO2006124874A3 (en) Inhibitors of b-raf kinase
WO2007079202A3 (en) Treatment for acute lymhoblastic leukemia
WO2006009975A3 (en) Histamine to treat disorders affecting muscle function
WO2007002836A3 (en) Methods and compositions for the prevention and treatment of kidney disease
WO2006086693A3 (en) Medical devices
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
WO2006116185A3 (en) Methods for the treatment of multiple myeloma
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
HK1102626A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
WO2005089426A3 (en) Method of treating sepsis
WO2008014603A3 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
WO2006053014A3 (en) Selective inhibition of rock1 in cardiac therapy
WO2005105135A8 (en) Il-6 for therapy or prevention of chemotherapy-induced neuropathy
WO2002041831A3 (en) Inositol derivatives for increasing chloride secretion and inhibiting inflammation
WO2006044582A3 (en) Use of baff to treat sepsis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase